{
    "clinical_study": {
        "@rank": "97637", 
        "arm_group": [
            {
                "arm_group_label": "1: Acute Lymphoblastic Leukemia/Lymphoma", 
                "arm_group_type": "Experimental", 
                "description": "Days -6 through -3:  Busulfan q 5-6h IV q24h x 4 days*\nDays -2 and -1:  Cyclophosphamide 50mg/kg/day IV x 2 days+  Mesna 40 mg/kg/day IV+\nDay 0:  Infuse unmanipulated bone marrow\nDay +3 and +4:  Cyclophosphamide 50 mg/kg/day IV#  Mesna 40 mg/kg IBW/day IV#\nDay +5:  Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day\nDay +30 Assess chimerism and disease status in bone marrow\nDay +35             Discontinue MMF\nDay +60    Assess chimerism and disease status in bone marrow\nDay 180    Discontinue tacrolimus"
            }, 
            {
                "arm_group_label": "2: Acute Lymphocytic Leukemia/Lymphoma", 
                "arm_group_type": "Experimental", 
                "description": "Days -5 through -4:  Cyclophosphamide 50mg/kg/day IV q24h  x 2 days+Mesna 40 mg/kg/day IV+\nDays -3 through -1:   TBI 200 cGy twice a day for 3 days\nDay 0:  Infuse unmanipulated bone marrow\nDay +3 and +4:  Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV\nDay +5:   Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day\nDay +30 Assess chimerism and disease status in bone marrow\nDay +35:  Discontinue MMF\nDay +60:  Assess chimerism and disease status in bone marrow\nDay 180                 Discontinue tacrolimus"
            }
        ], 
        "brief_summary": {
            "textblock": "We propose a multi-institutional phase II haplo-identical T cell replete BMT study in\n      children with high-risk leukemias. The myeloablative conditioning regimen prescribed will be\n      TBI-based for lymphoid leukemias and busulfan-based for myeloid leukemias. Our goal is to\n      establish an easily exportable, inexpensive platform for haplotransplantation that has a\n      safety profile equivalent to matched related and unrelated BMTs. The primary objective will\n      be to estimate the incidence of 6-month non-relapse mortality, hypothesizing that NRM is <\n      18%."
        }, 
        "brief_title": "Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myeloablative Conditioning", 
            "HLA-mismatched Bone Marrow Transplantation"
        ], 
        "condition_browse": {
            "mesh_term": "Hematologic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient age 0.5-25years\n\n          -  Patients must have a first-degree related donor or half-sibling who is at   minimum\n             HLA haploidentical. The donor and recipient must be identical at at least one allele\n             of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.\n             A minimum match of 5/10 is therefore required, and will be considered sufficient\n             evidence that the donor and recipient share one HLA haplotype.\n\n          -  An unrelated donor search is not required for a patient to be eligible for this\n             protocol, or a donor search and donor mobilization may be abandoned if the clinical\n             situation dictates an urgent transplant.  Clinical urgency is defined as 6-8 weeks\n             from referral to transplant or a low-likelihood of finding a matched, unrelated\n             donor. Patients with an eligible HLA-matched RELATED should not be enrolled on this\n             trial.\n\n          -  Patients must have at least one of the following high-risk conditions listed below\n             (criteria are meant to complement existing criteria within COG protocols):\n\n          -  Acute lymphocytic leukemia (ALL) in CR1* as defined by at least one of the following:\n\n        hypodiploidy induction failure MRD after consolidation\n\n        - Acute myeloid leukemia (AML) in CR1 with high risk features defined as: High allelic\n        ratio FLT3/ITD+ Monosomy 7 Del (5q) Standard risk cytogenetics with positive minimal\n        residual disease at the end of Induction I chemotherapy (for patients being treated on or\n        according to COG AAML1031 who have had MRD studies sent to Seattle or performed at their\n        local institution where the flow assay is sensitive enough to detect > 0.1% blasts)\n\n          -  Acute Leukemias in 2nd or subsequent CR (CR>2)\n\n          -  Mixed phenotype/Undifferentiated Leukemias in 1st or subsequent CR*\n\n          -  Secondary or therapy related leukemias in CR  > 1\n\n          -  NK cell leukemia or NK cell lymphoblastic leukemia/lymphoma CR > 1 Myelodysplastic\n             syndrome (MDS)\n\n          -  JMML (patients are eligible if they are not eligible for COG1221)\n\n          -  Prior transplant eligible if  < 18yo, >6 months has elapsed since BMT, and patient is\n             off immunosuppression for > 3 months with no GVHD\n\n          -  No known active CNS involvement or extramedullary involvement by malignancy. Such\n             disease treated into remission is permitted.\n\n          -  Acute Leukemia - Remission is defined as morphology with < 5% blasts with no\n             morphological characteristics of acute leukemia (e.g., Auer Rods) in a bone marrow\n             with > 20% cellularity.\n\n        Exclusion Criteria:\n\n          -  Patients will not be excluded on the basis of sex, racial or ethnic background.\n\n          -  Poor cardiac function: left ventricular ejection fraction <45% as determined by MUGA\n             or ECHO. For pediatric patients LVEF <45% or a shortening fraction below normal\n             limits for age.\n\n          -  Symptomatic pulmonary disease. Poor pulmonary function: FEV1, FVC, and DLCO <50%\n             predicted (corrected for hemoglobin) for patients who have not received thoracic or\n             mantle irradiation. For patients who have received thoracic or mantle irradiation,\n             FEV1 and FVC <70% predicted or DLCO < 50 of predicted. For children unable to perform\n             PFTs because of developmental stage pulse oximetry < 92% on RA.\n\n          -  Poor liver function: bilirubin >2 mg/dl (not due to hemolysis, Gilbert's or primary\n             malignancy). ALT or AST > 3 x laboratory upper normal limits.\n\n          -  Poor renal function: Creatinine >2.0mg/dl or creatinine clearance (calculated\n             creatinine clearance is permitted) < 60 mL/min based on Traditional Cockcroft-Gault\n             formula: 140 - age (yrs) x Smaller of Actual Weight vs. Ideal Body Weight (kg)  / 72\n             x Serum creatinine (mg/dl) Multiply by another factor of 0.85 if female Intended for\n             ages 18-110, serum creatinine 0.6-7 mg/dl For patients <18 years: CrCl will be\n             estimated by the Schwartz formula. A measured CrCl or a GFR may be substituted to\n             determine the subject's CrCl.\n\n          -  Schwartz equation: CrCl (ml/min/1.73m2)=[length (cm) x k] /serum creatinine K = 0.45\n             for infants 1 to 52 weeks old k = 0.55 for children 1 to 13 years old k = 0.55 for\n             adolescent females 13-18 years old k = 0.7 for adolescent males 13-18 years old\n\n          -  HIV-positive\n\n          -  Positive leukocytotoxic crossmatch Specifically, complement dependent cytotoxicity\n             and flow cytometric crossmatch assays must be negative, and the mean fluorescence\n             intensity (MFI) of any anti-donor HLA antibody by solid phase immunoassay should be\n             <3000.  Consult with PI for the clinical significance of any anti-donor antibody.\n\n          -  Women of childbearing potential who currently are pregnant (HCG+) or who are not\n             practicing adequate contraception or who are breastfeeding\n\n          -  Uncontrolled viral, bacterial, or fungal infections (currently taking medication and\n             have progression of clinical symptoms) Patients with symptoms consistent with RSV,\n             influenza A, B, or parainfluenza at the time of enrollment will be assayed for the\n             above viruses and if positive are not eligible for the trial until they are no longer\n             symptomatic (patients may have continued assay positivity for a period of time post\n             resolution of symptoms secondary to the nature of the assay"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120157", 
            "org_study_id": "J13161", 
            "secondary_id": "NA_00091665"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1: Acute Lymphoblastic Leukemia/Lymphoma", 
                    "2: Acute Lymphocytic Leukemia/Lymphoma"
                ], 
                "description": "Chemotherapy administration", 
                "intervention_name": "Post-transplantation Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2: Acute Lymphocytic Leukemia/Lymphoma", 
                "description": "Radiation Therapy", 
                "intervention_name": "TBI cGy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "1: Acute Lymphoblastic Leukemia/Lymphoma", 
                "description": "Chemotherapy Administered", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1: Acute Lymphoblastic Leukemia/Lymphoma", 
                    "2: Acute Lymphocytic Leukemia/Lymphoma"
                ], 
                "description": "Bone Marrow Transplant", 
                "intervention_name": "Bone Marrow Infusion", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "1: Acute Lymphoblastic Leukemia/Lymphoma", 
                    "2: Acute Lymphocytic Leukemia/Lymphoma"
                ], 
                "description": "Immunosuppressive Drug Administered", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1: Acute Lymphoblastic Leukemia/Lymphoma", 
                    "2: Acute Lymphocytic Leukemia/Lymphoma"
                ], 
                "description": "Immunosuppressive Drug Administered", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": "MMF"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Cyclophosphamide", 
                "Mycophenolate mofetil", 
                "Tacrolimus", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Acute lymphoblastic leukemia", 
            "Acute myeloid leukemia", 
            "Juvenile myelomonocytic leukemia", 
            "Treatment related leukemia", 
            "Biphenotypic leukemia"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "Johns Hopkins Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Heather Symons, MD, MHS", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Elias Zambidis, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Loeb, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Allen Chen, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christopher Gamper, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T Cell Replete Bone Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies", 
        "overall_contact": {
            "email": "hsymons2@jhmi.edu", 
            "last_name": "Heather Symons, MD, MHS", 
            "phone": "410-502-4997"
        }, 
        "overall_official": {
            "affiliation": "SKCCC Johns Hopkins Hospital", 
            "last_name": "Heather Symons, MD, MHS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To estimate the incidence of non-relapse mortality at 180 days following myeloablative, HLA-mismatched BMT for patients with high risk hematologic malignancies", 
            "measure": "Incidence of Mortality", 
            "safety_issue": "No", 
            "time_frame": "Day 180"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Estimate the incidence of donor cell engraftment at Day 60 following myeloablative, HLA-mismatched BMT.  Estimate the time to neutrophil and platelet recovery.  Estimate the incidence of primary and secondary graft failure.\nEstimate the cumulative incidence of acute GVHD grades 2-4 and grades 3-4 using competing risk analysis Estimate the cumulative incidence of chronic GVHD using competing risk analysis.  Characterize the duration of use, number, and type of steroid and non-steroid immunosuppressants used to treat GVHD. Estimate overall survival (OS), relapse, progression-free survival, disease-free survival, event-free survival, and relapse-free GVHD-free survival in patients receiving myeloablative, HLA-mismatched BMT for patients with high risk hematologic malignancies at 1 year and 2 years. Assess hematologic and non-hematologic toxicities of myeloablative haploidentical BMT. Characterize immune reconstitution post myeloablative haploidentical BMT with PT/Cy.", 
            "measure": "Donor Cell Engraftment", 
            "safety_issue": "No", 
            "time_frame": "Day 60"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}